These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
873 related articles for article (PubMed ID: 33667602)
1. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment. He B; Wang L; Xu B; Zhang Y; Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602 [TBL] [Abstract][Full Text] [Related]
2. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
3. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D; Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532 [TBL] [Abstract][Full Text] [Related]
4. The Role of Apolipoprotein E ε4 in Early and Late Mild Cognitive Impairment. Luo Y; Tan L; Therriault J; Zhang H; Gao Y; Eur Neurol; 2021; 84(6):472-480. PubMed ID: 34340229 [TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting. Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S; Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118 [TBL] [Abstract][Full Text] [Related]
8. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status. Rehman H; Ang TFA; Tao Q; Espenilla AL; Au R; Farrer LA; Zhang X; Qiu WQ; J Alzheimers Dis; 2024; 97(2):621-633. PubMed ID: 38143358 [TBL] [Abstract][Full Text] [Related]
12. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Ben Bouallègue F; Mariano-Goulart D; Payoux P; Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967 [TBL] [Abstract][Full Text] [Related]
13. Patients with Alzheimer's disease have an increased removal rate of soluble beta-amyloid-42. Zaretsky DV; Zaretskaia MV; Molkov YI; PLoS One; 2022; 17(10):e0276933. PubMed ID: 36315527 [TBL] [Abstract][Full Text] [Related]
14. A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease. Senda M; Ishii K; Ito K; Ikeuchi T; Matsuda H; Iwatsubo T; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikari Y; Niimi Y; Arai H; Tamaoka A; Arahata Y; Itoh Y; Tachibana H; Ichimiya Y; Washizuka S; Odawara T; Ishii K; Ono K; Yokota T; Nakanishi A; Matsubara E; Mori H; Shimada H J Prev Alzheimers Dis; 2021; 8(4):495-502. PubMed ID: 34585225 [TBL] [Abstract][Full Text] [Related]
15. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study. Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253 [TBL] [Abstract][Full Text] [Related]
16. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. Zwan M; van Harten A; Ossenkoppele R; Bouwman F; Teunissen C; Adriaanse S; Lammertsma A; Scheltens P; van Berckel B; van der Flier W J Alzheimers Dis; 2014; 41(3):801-7. PubMed ID: 24705549 [TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia. Hosseini AA; Brown T; Mannino L; Gran B; Junaid K; Mukaetova-Ladinska EB J Alzheimers Dis; 2022; 87(2):771-780. PubMed ID: 35404281 [TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817 [TBL] [Abstract][Full Text] [Related]
19. Elevated Inflammatory Markers and Arterial Stiffening Exacerbate Tau but Not Amyloid Pathology in Older Adults with Mild Cognitive Impairment. Clark AL; Weigand AJ; Thomas KR; Solders SK; Delano-Wood L; Bondi MW; Bernier RA; Sundermann EE; Banks SJ; Bangen KJ; J Alzheimers Dis; 2021; 80(4):1451-1463. PubMed ID: 33682714 [TBL] [Abstract][Full Text] [Related]
20. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]